Clinical Trials
3
Active:0
Completed:3
Trial Phases
2 Phases
Phase 3:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (66.7%)Not Applicable
1 (33.3%)Risk Score Alerts for Chest Pain Care
Phase 3
Completed
- Conditions
- Acute Myocardial InfarctionChest Pain
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Harvard Vanguard Medical Associates
- Target Recruit Count
- 8000
- Registration Number
- NCT00674375
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Harvard Vanguard Medical Associates, Newton, Massachusetts, United States
Improving Diabetes Care for African Americans
Phase 3
Completed
- Conditions
- Diabetes
- First Posted Date
- 2007-02-16
- Last Posted Date
- 2009-03-23
- Lead Sponsor
- Harvard Vanguard Medical Associates
- Target Recruit Count
- 6000
- Registration Number
- NCT00436176
- Locations
- 🇺🇸
Harvard Vanguard Medical Associates, Newton, Massachusetts, United States
Improving Followup of Abnormal Colon Cancer Screening Tests
Not Applicable
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2007-02-16
- Last Posted Date
- 2008-11-06
- Lead Sponsor
- Harvard Vanguard Medical Associates
- Target Recruit Count
- 70
- Registration Number
- NCT00436137
- Locations
- 🇺🇸
Harvard Vanguard Medical Associates, Newton, Massachusetts, United States
News
Catalyst Pharmaceuticals Appoints Dr. William Andrews as Chief Medical Officer to Lead Rare Disease Strategy
Catalyst Pharmaceuticals appointed Dr. William T. Andrews as Chief Medical Officer, succeeding retiring Dr. Gary Ingenito after his successful 10-year tenure with the company.